19.10.2016 Evonik Industries AG  DE000EVNK013

DGAP-News: Evonik Industries AG: Evonik starts construction of second methionine complex in Singapore


 
DGAP-News: Evonik Industries AG / Key word(s): Miscellaneous Evonik Industries AG: Evonik starts construction of second methionine complex in Singapore 19.10.2016 / 10:30 The issuer is solely responsible for the content of this announcement. --------------------------------------------------------------------------- Evonik starts construction of second methionine complex in Singapore * DL-methionine in continued demand for animal nutrition * Investment of more than half a billion euros * Doubling the production capacity in Singapore to 300,000 metric tons per year Essen/Singapore. Evonik Industries plans to build a second world-scale plant for the production of the amino acid DL-methionine in Singapore are fully on schedule. The company marked the official start of construction with a symbolic ground-breaking ceremony today, officiated by Tharman Shanmugaratnam, Singapore Deputy Prime Minister & Coordinating Minister for Economic and Social Policies. The complex will have an annual production capacity of 150,000 metric tons and is expected to become operational in 2019, with investment costs of more than half a billion euros. Evonik sells DL-methionine under the brand name MetAMINO(R). "Our methionine complex, which came on-stream in late 2014 on Jurong Island, is a success story. This led to our decision to build a second plant next to it," said Klaus Engel, the chairman of the Executive Board of Evonik Industries, in Singapore today. "The demand for MetAMINO(R) for animal nutrition is continuing to grow at a very fast rate in Asia." The new plant will not only produce methionine, but also all strategically important precursors to guarantee product quality and supply security. "Singapore has proven an ideal location for supplying our Asian customers," said Reiner Beste, chairman of the Board of Management of Evonik Nutrition & Care GmbH. The new complex will create more than 150 jobs at the location. "We are pleased to have such qualified personnel available to us in this country," Beste continued. The new production complex will increase Evonik's annual capacity of MetAMINO(R) to a total of approximately 300,000 metric tons in Asia, and to approximately 730,000 metric tons worldwide. The specialty chemicals company produces the amino acid in its world-scale plants in Antwerp (Belgium), Wesseling/Cologne (Germany), Mobile (Alabama, USA), and Singapore. DL-methionine is an essential amino acid, which must be absorbed through feed intake. As a feed additive, it contributes to the efficient, healthy and environmentally friendly nutrition of livestock, particularly poultry and swine. That makes it an important component of ensuring a sustainable animal protein supply for the world's growing population. Evonik has over 60 years of experience in the manufacture of essential amino acids and provides solutions for efficient and sustainable animal nutrition to customers in over one hundred countries. Evonik wants to make an even greater contribution to the efficiency of animal feed by supplementing its portfolio with innovative feed additives beyond amino acids in order to create additional value for its customers. Evonik's products and services in the area of animal nutrition play a key role worldwide in the production of healthy and affordable food, while preserving natural resources and reducing the ecological footprint. Company information Evonik, the creative industrial group from Germany, is one of the world leaders in specialty chemicals. Profitable growth and a sustained increase in the value of the company form the heart of Evonik's corporate strategy. Its activities focus on the key megatrends health, nutrition, resource efficiency and globalization. Evonik benefits specifically from its innovative prowess and integrated technology platforms. Evonik is active in over 100 countries around the world. In fiscal 2015 more than 33,500 employees generated sales of around EUR13.5 billion and an operating profit (adjusted EBITDA) of about EUR2.47 billion. About Nutrition & Care The Nutrition & Care segment is led by Evonik Nutrition & Care GmbH and contributes to fulfilling basic human needs. That includes applications for everyday consumer goods as well as animal nutrition and health care. This segment employed about 7,000 employees, and generated sales of around EUR4.9 billion in 2015. Disclaimer In so far as forecasts or expectations are expressed in this Investor Relations News or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release. Contact: Tim Lange Head of Investor Relations +49 201 177-3150 tim.lange@evonik.com Evonik Industries AG Rellinghauser Straße 1-11 45128 Essen Germany Phone +49 201 177-01 Fax +49 201 177-3475 www.evonik.com Supervisory Board Dr. Werner Müller, Chairman Executive Board Dr. Klaus Engel, Chairman Christian Kullmann, Deputy Chairman Dr. Ralph Sven Kaufmann Thomas Wessel Ute Wolf Registered Office is Essen Register Court Essen Local Court Commercial Registry B 19474 --------------------------------------------------------------------------- 19.10.2016 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de --------------------------------------------------------------------------- Language: English Company: Evonik Industries AG Rellinghauser Straße 1-11 45128 Essen Germany Phone: +49 (0) 201 177-01 Fax: +49 (0) 201 177-3475 E-mail: investor-relations@evonik.com Internet: www.evonik.com ISIN: DE000EVNK013, XS0911405784 WKN: EVNK01, A1TM7T Indices: MDAX Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange; Luxemburg End of News DGAP News Service --------------------------------------------------------------------------- 512427 19.10.2016


Die wichtigsten Finanzdaten auf einen Blick
  2013 2014 2015 2016 2017 2018 2019 2020e
Umsatzerlöse1 12.874,00 12.917,00 13.507,00 12.732,00 14.419,00 15.024,00 13.108,00 13.140,00
EBITDA1,2 1.995,00 1.822,00 2.465,00 2.165,00 2.357,00 2.150,00 2.153,00 2.140,00
EBITDA-Marge3 15,50 14,11 18,25 17,00 16,35 14,31 16,43 16,29
EBIT1,4 1.424,00 1.046,00 1.644,00 1.298,00 1.229,00 1.367,00 1.080,00 0,00
EBIT-Marge5 11,06 8,10 12,17 10,19 8,52 9,10 8,24 0,00
Jahresüberschuss1 2.054,00 581,00 1.019,00 762,00 734,00 954,00 2.127,00 0,00
Netto-Marge6 15,95 4,50 7,54 5,98 5,09 6,35 16,23 0,00
Cashflow1,7 1.083,00 1.066,00 1.968,00 1.758,00 1.551,00 1.704,00 1.321,00 0,00
Ergebnis je Aktie8 1,78 1,22 2,13 1,81 1,54 2,00 4,52 1,65
Dividende8 1,00 1,00 1,15 1,15 1,15 1,15 1,15 0,75
Quelle: boersengefluester.de und Firmenangaben

  Geschäftsbericht 2019 - Kostenfrei herunterladen.  
1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de

Wirtschaftsprüfer: PricewaterhouseCoopers

INVESTOR-INFORMATIONEN
©boersengefluester.de
Evonik Industries
WKN Kurs in € Einschätzung Börsenwert in Mio. €
EVNK01 22,020 Halten 10.261,32
KGV 2021e KGV 10Y-Ø BGFL-Ratio Shiller-KGV
11,59 14,98 0,773 10,17
KBV KCV KUV EV/EBITDA
1,22 7,77 0,78 7,625
Dividende '19 in € Dividende '20e in € Div.-Rendite '19e
in %
Hauptversammlung
1,15 0,75 5,22 31.08.2020
Q1-Zahlen Q2-Zahlen Q3-Zahlen Bilanz-PK
07.05.2020 04.08.2020 03.11.2020 04.03.2020
Abstand 60Tage-Linie Abstand 200Tage-Linie Performance YtD Performance 52 Wochen
-8,26% -6,40% -19,07% -2,39%
    
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu Evonik Industries AG  ISIN: DE000EVNK013 können Sie bei DGAP abrufen

Chemie , EVNK01 , EVK , XETR:EVK